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INTRODUCTION 
Human Immunodeficiency Virus (HIV) infection is spreading 
worldwide in pandemic proportions. It manifests from an asymptomatic 
state to AIDS. Involvement of multiple organs is well documented. Renal 
involvement occurs due to infection per se or due to associated problems 
like opportunistic/co-infections, septicaemia, drug toxicity1,2. Renal disease 
was first reported in HIV-1–seropositive individuals in 1984, and initial 
reports identified focal segmental glomerulo-sclerosis (FSGS) and other 
renal disease. Renal involvement is seen in all stages of infection 
presenting as fluid and electrolyte imbalance, HIV associated nephropathy 
(HIVAN) progressing to End Stage renal Disease (ESRD). 
Survival of patients with HIV after HAART therapy has been 
introduced, has increased and so are the number of HIV cases with Chronic 
Kidney Disease (CKD)3. Cohort studies suggest that approximately 30% of 
HIV-positive individuals have proteinuria (≥ 1+)4. 
            Microalbuminuria is an independent and earliest marker of          
renal involvement and loss of endothelial integrity. Overall 
microalbuminuria is seen in ~ 20% (varying from 9% to 30% in various 
studies) of untreated HIV infected patients5,6,7,8,9,10. Microalbuminuria 
levels showed correlation with CD4 T cell count suggesting an association 
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between the progression of disease and microalbuminuria8,9. Present study 
was undertaken to confirm or refute the earlier reports. 
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AIM & OBJECTIVES 
 
1.     To estimate the prevalence of microlalbuminuria in HIV patients 
 
2.     To correlate prevalence of microalbuminuria with CD4 cell count. 
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REVIEW OF LITERATURE 
HUMAN IMMUNODEFICIENCY VIRUS11 
 The origin of HIV is unclear. In 1983 it was isolated from a patient 
with lymphadenopathy and in 1984 it was demonstrated clearly to be the 
causative agent of AIDS11. India's first case of AIDS was reported in 1986 
from Chennai12.  
EPIDEMIOLOGY 
GLOBAL SCENARIO13:  
 An estimated 33 million people [30.3 – 36.1 million] were living with 
HIV in 2007. 
 There were 2.7 million [2.2 – 3.2 million] new HIV infections and 2 
million [1.8 – 2.3 million] AIDS-related deaths in 2007. 
 Number of children younger than 15 years living with HIV 2.0 
million (1.9-2.3 million) in 2007. 
 An estimated 370 000 [330 000–410 000] children younger than 15 
years became infected with HIV in 2007. 
 The rate of new HIV infections has fallen in several countries barring 
Sub-Saharan Africa. 
 Sub- Saharan Africa continues to dominate the statistics with 22.5 
million of Adults and Children living with HIV. 
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 Globally, women account for half of all HIV infections—this 
percentage has remained stable for the past several years. 
 The total number of children living with HIV has increased from 1.6 
million [1.4 – 2.1 million] in 2001 to 2 million [1.9 – 2.3 million] in 
2007 - almost 90% live in sub-Saharan Africa. 
INDIAN SCENARIO13,14: 
 Number of people living with HIV: 2 400 000. 
 India ranks 3rd in total number of HIV patients in a country. 
 Adults aged 15 to 49 prevalence rate: 0.3%. 
 Adults aged 15 and up living with HIV: 2 300 000. 
 Women aged 15 and up living with HIV: 880 000. 
 Percentage of coverage of ART for prevention of mother to child 
transmission: <25%. 
 Prevalence was higher in urban areas than in rural areas. 
 Prevalence was higher among male than female in all age groups 
except those 15 to 19 years of age, in which rates were very low. 
 HIV prevalence was stable or declining among pregnant women in the 
high prevalence states of Andhra Pradesh, Karnataka and Tamil Nadu. 
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 HIV transmission is primarily sexual, except in northeastern India 
where there is high rate of spread through injection-drug use. 
SCENARIO IN TAMILNADU 15 
HIV prevalence in different population is as follows 
¾ Antenatal clinic attendees – 0.25%.  
¾ STD clinic attendees – 8%. 
¾ Female sex workers – 4.62%. 
¾ Men having sex with men – 5.60%. 
¾ Intra venous drug abusers – 24.2%. 
District Categorization 15 
z Category A: More than 1% ANC prevalence in district in any of 
the sites in the last 3 years.  
z Category B: Less than 1% ANC prevalence in all the sites during       
last 3 years with more than 5% prevalence in any HRG site 
(STD/FSW/MSM/IDU).  
z Category C: Less than 1% ANC prevalence in all sites during last 
3 years with less than 5% in all HRG sites, with known hot spots 
(Migrants, truckers, large aggregation of factory workers, tourist 
etc).  
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z Category D: Less than 1% ANC prevalence in all sites during last  
3 years with less than 5% in all HRG sites with no known hot spots 
and no or poor HIV data.  
z In Tamil Nadu, among 30 districts, 22 districts are in category A,               
5 districts are in category B and 3 districts are in category C.  
ETIOLOGIC AGENT11 
              The etiologic agent of AIDS is Human Immunodeficiency Virus 
(HIV) which belongs to the family of human retroviruses (Retroviridae) 
and the sub family of lentiviruses. There are two subtypes of HIV namely 
HIV-1 and HIV-2. They are cytopathic viruses. HIV-1 was discovered by 
Luc Montagnier and his associates at the Institute of Pasteur in Paris in 
1983. HIV-2 is more similar to SIV (Simian Immunodeficiency Virus) than 
HIV-1 and is much less virulent usually not resulting in full blown AIDS, 
but still fatal. 
MORPHOLOGY OF HIV11 
               Electron microscopy shows that the HIV is spherical enveloped 
virus, about 90- 120 nm in size. The nucleocapsid has an outer icosahedral 
shell containing numerous external spikes formed by the two major 
envelope proteins, the external gp 120 and the transmembrane gp 41. The 
core virus particle is composed of ribonucleoproteins. 
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HIV GENOME11 
               HIV-1 has the following genes. Gag – encodes the proteins that 
form the core of virion. pol – encodes viral enzymes necessary for 
replication, reverse transcriptase, integrase and protease. env – encode  
glycoprotein. It also contains atleast six other genes tat, rev, nef, vpr, vpu 
which code for proteins involved in the regulation of gene expression. 
 The major difference between the genomes of HIV-1 and HIV-2 is 
the fact that HIV-2 lacks the vpu gene and has vpx gene not contained in 
HIV-1. 
LIFE CYCLE11 
ATTACHMENT AND ENTRY          
      The replication cycle of HIV begins with the high affinity binding of 
the gp 120 protein via a portion of its v1 region near the N terminus to its 
receptor on the host cell surface, the CD4 molecule. It is also expressed on 
the surface of monocytes and dentrites /langerhans cells. Once gp 120 
binds to CD4, the gp 120 undergoes a conformational change that 
facilitates binding to one of a group of co-receptors. The two major co-
receptors are CCR5 and CXCR4. 
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REVERSE TRANSCRIPTION AND INTEGRATION 
 Following binding of the envelope protein to the CD4 molecule, the 
virus is “uncoated” and the viral RNA is converted into complementary 
DNA (C-DNA) by virion associated reverse transcriptase enzyme. The C-
DNA is transported to the host cell nucleus and eventually gets 
incorperated into the host cell chromosomes by virus specific integrase 
enzyme. 
TRANSCRIPTION, TRANSLATION AND REPLICATION 
 The integrated DNA is transcribed into messenger RNA (mRNA) 
which comes out into cytoplasm and viral proteins are synthesized using 
protein synthesizing machinery and raw material from the host cell. Some 
of the viral proteins are synthesized as polyproteins that are eventually 
cleared by the proteinase enzyme. 
MATURATION AND RELEASE     
 Newly synthesized progeny RNA and proteins are packaged 
together and the newly formed virus particles are released from the infected 
cell by the budding process. 
PROGRESSION OF ILLNESS11 
 The median time from primary HIV infection to the development of  
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AIDS in untreated individuals is approximately 10 years. Individuals are 
considered to be long term survivors if they remain alive for ≥ 20 years 
after initial infection. It may be related to beneficial effect of ART and 
prophylaxis against opportunistic infections. Long term nonprogressors are 
those who have been infected with HIV for ≥ 10 years whose CD4 count 
are in the normal range and remained stable over years and who had not 
received ART.   
The reasons being11,16,17 
1. Mutant nef gene of HIV 
2. Heterozygosity for CCR5- ∆32 deletion 
3. Heterozygosity for CCR2-64I mutation 
4. Homozygosity for SDF1-3’A mutation  
5. Heterozygosity for the RANTES-28G mutation  
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CLASSIFICATION11                                                          
Table-1 
Clinical categories 
A B C CD4+ cell 
count(per 
microlitre) 
Categories 
Asymptomatic, 
Acute 
(primary) HIV 
or PGL 
Symptomatic, 
Not A or C 
Conditions 
AIDS- 
Indicator 
Conditions 
>500/µl A1 B1 C1 
200-499/µl A2 B2 C2 
<200/ µl A3 B3 C3 
 
PGL – Progressive Generalized Lymphadenopathy 
HIV infected persons classified in A3, B3, C1, C2 and C3 are AIDS 
cases 
Category A: 
 One or more of the following conditions in adolescents or adults 
(>13 years) with documented HIV infection. 
Conditions listed in categories B and C must not have occurred. 
1. Asymptomatic HIV infection 
 
2. Progressive Generalized Lymphadenopathy 
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3. Acute (primary) HIV infection with accompanying  illness or 
           history of acute HIV infection 
Category B: 
               Consists of symptomatic conditions in an HIV infected adolescent 
or adult that are not included among conditions listed in clinical category C 
and that meets one of the following criteria 
1. The  conditions are attributed to HIV infection or are indicative of  
 
  a defect in cell mediated immunity (CMI). 
 
2. Conditions are considered by physicians to have a clinical course  
 
           or to require management that is complicated by HIV infection. 
 
Examples include, but are not limited to the following 
a. Bacillary angiomatosis 
b. Candidiasis, oropharyngeal (thrush) 
 
c. Candidiasis, vulvovaginal: persistent, frequent or poorly responsive           
to therapy 
d. Cervical dysplasia (moderate or severe)/ cervical carcinoma in situ 
 
e. Constitutional symptoms, fever or diarrhea lasting >1 month 
 
f. Oral hairy leukoplakia 
 
g. Herpes zoster involving at least 2 distinct episodes or more than             
one dermatome. 
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h. Idiopathic thrombocytopenic purpura 
 
i. Listeriosis 
 
j. Pelvic inflammatory disease, particularly complicated by tubo 
ovarian abscess 
k. Peripheral neuropathy 
 
Categoty C: 
Conditions listed in AIDS surveillance case definition 
a. Candidiasis of  bronchi, trachea or lungs 
 
b. Candidiasis, esophageal 
 
c. Cervical cancer, invasive 
 
d. Coccidioidomycosis, disseminated or extrapulmonary 
 
e. Cryptococcosis, extrapulmonary 
 
f. Cryptosporidiosis, chronic intestinal (>1 month duration) 
 
g. Cytomegalovirus disease (other than liver, spleen or nodes) 
 
h. Cytomegalovirus retinitis (with loss of vision) 
 
i. Encephalopathy, HIV related 
 
j. Herpes simplex: chronic ulcers (>1 month duration) or  
 
bronchitis, pneumonia or esophagitis 
 
k. Histoplasmosis, disseminated or extra pulmonary 
 
l. Isosporiasis, chronic intestinal (>1 month duration)  
 
m. Kaposi’s sarcoma 
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n. Lymphoma, Burkitt’s (or equivalent term) 
 
o. Lymphoma, primary of  brain 
 
p. Mycobacterium avium complex or M. kansasii, disseminated  or 
extrapulmonary 
q. Mycobacterium tuberculosis, any site (pulmonary or 
extrapulmonary) 
 
r. Mycobacterium, other species or unidentified species, disseminated 
or extrapulmonary 
 
s. Pneumocystis jiroveci pneumonia 
 
t. Pneumonia, recurrent 
 
u. Progressive multifocal leukoencephalopathy 
 
v. Salmonella septicemia, recurrent 
 
w. Toxoplasmosis of brain 
 
x. Wasting syndrome due to HIV 
 
CLASSIFICATION OF HIV INFECTION (WHO 
CLINICAL STAGING SYSTEM)18 
Clinical stage 1: 
a. Asymptomatic  
b. Persistent Generalized Lymphadenopathy 
15 
 
Clinical stage 2: 
a. Weight loss <10% of body weight 
b. Recurrent upper respiratory tract infections (e.g. bacterial sinusitis) 
c. Herpes zoster 
d. Angular cheilitis 
e. Recurrent oral ulceration 
f. Papular pruritic eruptions 
g. Seborrhoeic dermatitis 
h. Fungal nail infections 
Clinical stage 3: 
a. Weight loss > 10% of body weight 
b. Unexplained chronic diarrhea > 1 month 
c. Unexplained persistent fever (intermittent or constant) > 1 month 
d. Persistent Oral Candidiasis (thrush) 
e. Oral hairy leukoplakia 
f. Pulmonary tuberculosis 
g. Severe bacterial infections (e.g. pneumonia, pyomyositis) 
h. Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
i. Unexplained anemia (< 8 g / dl), neutropenia (< 0.5 X 109 / litre) 
and or chronic thrombocytopenia 
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Clinical stage 4: 
a. HIV wasting syndrome 
b. Pneumocystis jiroveci pneumonia 
c. Recurrent severe bacterial pneumonia 
d. Toxoplasmosis of the brain 
e. Chronic Cryptosporidiosis 
f. Chronic Isosporiasis 
g. Cryptococcosis - extrapulmonary 
h. Cytomegalovirus infection (retinitis or infection of other organs) 
i. HIV Encephalopathy 
j. Chronic Herpes simplex infection  (orolabial, genital or anorectal of       
> 1 month’s duration or visceral at any site) 
k. Disseminated endemic mycosis (Extrapulmonary Histoplasmosis, 
Coccidiomycosis) 
l. Kaposi’s sarcoma 
m. Candidiasis - esophagus, trachea, bronchi or lungs 
n. Disseminated non-tuberculous  mycobacteria infection 
o. Mycobacterium tuberculosis, extrapulmonary 
p. Progressive multifocal leukoencephalopathy 
q. Recurrent septicemia (including non typhoid salmonella 
septicemia) 
17 
 
r. Lymphoma (Cerebral or B cell Non-Hodgkin) 
s. Invasive cervical carcinoma 
t. Atypical disseminated leishmaniasis  
u. Symptomatic HIV-associated nephropathy or symptomatic HIV 
associated cardiomyopathy 
 
WHO CASE DEFINITION FOR AIDS SURVEILLANCE IN ADULT 
WHERE HIV TESTING FACILITIES NOT AVAILABLE18 
 Case definition for AIDS is fulfilled if at least two major signs 
and one minor sign are present 
 
Major signs: 
a. Weight loss >10% of  body weight 
b. Chronic diarrhea >1 month 
c. Prolonged fever  >1 month 
Minor signs: 
a. Persistent cough >1 month 
b. History of herpes zoster 
c. Oropharyngeal candidiasis 
d. Generalized lymphadenopathy 
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e. Chronic progressive herpes simplex infection 
WHO GUIDELINES FOR INITIATION OF ART IN ADULTS AND 
ADOLESCENTS 18 
 
                                                   Table-2 
Classification of 
HIV associated 
clinical disease 
WHO 
clinical 
Stage 
CD4 test not 
available or 
pending 
CD4 test available 
Asymptomatic 1 Do not treat Treat if CD4 count < 200 
Mild symptoms 2 Do not treat Treat if CD4 count < 200 
Advanced 
symptoms 3 Treat 
Consider treating  if CD4     
≤ 350 and initiate  ART 
before CD4 drops below 200
Severe/Advanced 
symptoms 4 Treat 
Treat irrespective of CD4 
count 
 
 
NACO GUIDELINES FOR INITIATION OF ART IN ADULTS AND 
ADOLESCENTS 6 
Table-3 
CD4 
count   
(cells/µL) 
Actions 
< 200 Treat irrespective of clinical stage 
200 -350 
Offer ART for symptomatic patients.  Initiate 
treatment before CD4 drops below 200 
cells/µL in asymptomatic patients 
> 350 Defer treatment in asymptomatic persons 
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* If CD4 count is between 200- 250, this should be repeated in four 
weeks and treatment to be considered in asymptomatic patients. 
British HIV association (BHIVA) suggests initiation of  ART for 
asymptomatic HIV infected individuals having less than 200 CD4 T cell 
counts.70 International AIDS society recommends initiation of ART in 
asymptomatic individuals with CD4 count > 200 to 350 cells / µl and viral 
load 50000 - 100000 copies / ml20. 
  Ramalingam et al in a study conducted in 2001 have shown that  
mean CD4 counts in South Indian population both normal and HIV 
infected individuals  are lower than in western population and have 
proposed a modified classification based on CD4 cell count for South 
Indians. The categories of CD4 count proposed were cell count   >300,   
81-300,   ≤ 80 cells/µL, instead of      the   >500, 201-500, ≤ 200 
recommended by CDC21 
 Kannagai et al in a study conducted in 2008 have shown that   
majority of HIV infected individuals in South India with CD4 counts of       
200-350 cells/µL had higher viral load than that suggested by                   
International AIDS Society.22 
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MICROALBUMINURIA23,24 
DEFINITION 
 Microalbuminuria has been defined as Albumin excretion of 20 to  
200 µg/min or 30-300 mg/day in a 24 hours urinary sample, anything 
above this level of excretion is called macroalbuminuria25.  
Microalbuminuria is also defined in terms of the urinary albumin to 
creatinine ratio greater than 30 mg/g in the first voided sample in the 
morning. 
Table - 4 
Definition of abnormality in albumin excretion 
Category 
24-hrs 
collection   
(mg/24 hrs) 
Timed 
collection  
(µg/min) 
Spot 
collection 
(mg/gm cre) 
Normal < 30 < 20 < 30 
Microalbuminuria 30 - 299 20 - 199 30 - 299 
Clinical  Albuminuria ≥ 300 ≥ 200 ≥ 300 
 
 PATHOPHYSIOLOGY OF MICROALBUMINURIA 
 The glomerular capillary wall (GCW) provides a barrier to filtration 
of large macromolecules. It has 3 components. 
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i. Endothelium of the capillary 
ii. Basement membrane 
iii. Epithelial cells (podocytes) surrounding the outer surface of the 
capillary basement membrane        
            Together these make up the filtration barrier, which despite the 
three layers filters several hundred times as much water and solutes as the 
usual capillary membrane. Filterability of substance by glomerular 
capillaries decreases with increasing molecular weight. The barrier to 
filtration is provided by 2 mechanisms: 
Size selectivity and Charge selectivity 
 Size selectivity is a feature of the size of the pores of the 
components in the barrier. The endothelial cells have fenestrations with an 
approximate radius 40 nm and as such do not provide an effective barrier to 
albumin which has radius of 3.6 nm. The GBM has pores with a radius of 4 
nm. Between the foot processes of epithelial cells a thin membrane called 
slit diaphragm provides barrier to filtration. The pores in the slit membrane 
are the same size as those in GBM. The GBM and slit diaphragm are 
therefore the major components of size selectivity. 
 Charge selectivity is provided by negatively charged anions such 
as Heparan sulphate, Proteoglycan which repel negatively charged 
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molecules such as albumin. These anions are present both in Endothelium 
and GBM which thus provide charge selectivity. The negative charge in the 
GBM also may be important for adhesion of epithelial cells, such that loss 
of negative charge may result in disruption of epithelial cell barrier, which 
in turn contributes to increased permeability to macromolecules such as 
albumin(due to loss of size selectivity). 
  When damage to the basement membrane or components of 
glomerular epithelial cells occurs, often the first manifestation is the 
appearance of plasma proteins in urine. Since albumin is the major 
circulating plasma protein and is relatively close in size to that of size 
selectivity, its appearance in the urine is the most sensitive indicator of 
damage or disruption of integrity of glomerular filtration barrier.   
 
RENAL INVOLVEMENT IN HIV AND AIDS26,27,28 
 Several lines of evidence point to kidney disease as an important 
complication of human immunodeficiency virus (HIV) infection. Kidney 
function is abnormal in up to 30% of HIV–infected patients, AIDS-related 
kidney disease has become a relatively common cause of end-stage renal 
disease (ESRD) requiring dialysis, and kidney disease may be associated 
with progression to AIDS and death.29 
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Historical perspective 
 Rao et al30 in 1984 described focal and segmental 
glomerulosclerosis in nine patients with AIDS and Nephrotic syndrome. 
The changes were similar to heroin induced nephropathy. Progression to 
End Stage Renal Disease (ESRD) in these patients was much more 
rampant. In the same year Pardo et al31 reported a variety of glomerular 
changes seen at autopsy in patients with AIDS. Since then many reports 
have validated renal involvement in HIV infected population and a wide 
spectrum of renal syndromes have been reported. 
Spectrum of renal disease 
 The renal manifestations of HIV infection occur commonly during 
all stages of infection. Renal manifestations of HIV infection occurs in 6-
10% of seropositive individuals. A wide spectrum of renal syndromes has 
been associated with HIV infection. 
Overview of HIV related renal disease 
A. Acute Renal Failure 
       Pre renal 
¾ Hypovolemia – [Diarrhoea, Vomiting, Bleeding, Pancreatitis] 
¾ Hypoalbuminemia – [Severe malnutrition, Cirrhosis]  
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       Renal                                                                                                                 
       Mostly induced by drugs 
¾ Acute Tubular Necrosis – [Aminoglycosides, Amphotericin-B, 
Foscarnet, Pentamidine, Rhabdomyolysis] 
¾ Allergic Interstitial Nephritis – [Protease inhibitors, Phenytoin, 
Trimethoprim/Sulfamethoxazole, Cephalosporins] 
¾ Crystal deposition – [Protease inhibitors, Acyclovir, Sulfadiazine] 
       Post renal   
¾ External obstruction – [Tumour, Prostate hyperplasia, Urethral 
obstruction, Retroperitoneal fibrosis] 
¾ Internal obstruction – [ Crystal deposition, Blood clots, Tumour 
lysis] 
B. Chronic Kidney Disease 
Focal Glomerulosclerosis (Classic HIVAN) 
Immune complex disease 
¾ IgA nephropathy 
¾ Mixed sclerotic immune complex nephropathy 
¾ Proliferation glomerulosclerosis 
       Thromotic Microangiopathies  
¾ Hemolytic Uremic Syndrome (HUS) 
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¾ Thromotic Thrombocytopenic Purpura (TTP) 
       Renal Amyloidosis 
       Renal parenchymal invasion by malignancies 
              [Lymphoma, Kaposi’s sarcoma] 
C. Fluid and Electrolyte disturbances 
Hyponatremia  
¾ Fluid loss 
¾ SIADH 
¾ Infection – Toxoplasmosis, Tuberculosis, Pneumocystis 
¾ Adrenal insufficiency 
       Hyperkalemia  
¾ Adrenal insufficiency 
¾ Hyporeninemic Hypoaldosteronism 
¾ IDDM [Pentamidine induced, Pancreatic cell dysfunction] 
¾ Severe ARF  
       Hypokalemia  
¾ GI losses 
¾ Renal potassium wasting 
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       Metabolic Alkalosis 
¾ Upper GI loss 
¾ Hypokalemia 
       Metabolic Acidosis 
¾ Renal failure 
¾ Septic shock 
¾ Diarrhoea 
¾ Drug induced interstitial nephritis 
 
ACUTE RENAL FAILURE 
 The adults AIDS Clinical Trials Group has defined acute renal 
failure (ARF) in HIV-seropositive patients as a creatinine level greater than 
1.5 mg/dL or a 1.3-fold increase above laboratory baseline that resolves 
within 3 months29. The fundamental aetiology and mechanisms involved in 
acute renal Injury in HIV patients are generally the same as in non HIV 
patients. Acute deterioration in renal function may be due to pre renal, 
intrinsic to renal tissue and post renal causes. 
 In overwhelming number of patients with ARF pre renal aetiology 
is noted. Pre renal causes of ARF include hypovolemic states due to 
profuse vomiting, diarrhoea, infections, sepsis and excessive & life 
threatening bleeding. 
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 Intrinsic ARF in HIV infected patients may be due to hypovolemia, 
sepsis, shock and use of nephrotoxic agents for therapeutic and diagnostic 
purposes. Rhabdomyolysis, Use of NSAIDs, HUS & TTP are other causes 
of ARF. 
 Post renal ARF may be due to extra renal or distal obstruction. 
Intrinsic obstruction may also lead to post renal ARF. Outflow obstruction, 
retroperitoneal fibrosis and crystalluria may contribute to post              
renal ARF. Indinavir, Sulfadiazine and Acyclovir have been implicated   in 
crystalluria32. 
 
FLUID & ELECTROLYTE DISORDERS 
 Among the electrolyte abnormalities observed in HIV patients, 
hyponatremia and hyperkalemia are significant. 
Hyponatremia :- 
¾ It is the most common, involving 30-60% of hospitalized 
symptomatic HIV and AIDS patients. 
¾ Severe hyponatremia indicates poor prognosis33. 
¾ Volume depletion due to diarrhoea or vomiting is the usual cause of 
hyponatremia present at the time of  hospital admission. 
¾ Excess body water is attributed either to hypovolemia with 
physiologic stimulation of ADH, administration of hypotonic fluids 
or SIADH. 
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¾ SIADH is the usual culprit in those who develop hyponatremia 
during hospitalization34. 
¾ SIADH is usually associated with common pulmonary and 
intracranial diseases such as Pneumocystis pneumonia, 
Toxoplasmosis, Tuberculosis. 
¾ AIDS patients have a high incidence of adrenal abnormalities. 
Adrenal pathology particularly CMV infection is found common in 
patients who have died from AIDS35. Other pathologic lesions  that 
have been noted frequently include Hemorrhage, Toxoplasma 
infection, Cryptococcal infection, MAC, Infiltration with Kaposi’s 
sarcoma and Lymphoma.    
Hyperkalemia  
    Occurs as a result of  
¾ High dose of Trimethoprim-Sulfamethoxazole or IV Pentamidine. 
The underlying mechanism with both drugs consists of inhibition of 
distal nephron sodium transport, leading to a decrease in distal 
potassium secretion. Trimethoprim shares structural similarity with 
the potassium sparing diuretic Triamterene.  
¾ Hyperkalemia and hyponatremia may also be manifestation of 
mineralocorticoid deficiency due to adrenal insufficiency or the 
syndrome of hyporeninemic hypoaldosteronism36. 
29 
 
¾ A systemic abnormality in potassium equilibrium which favours the 
development of hyperkalemia by a mechanism unrelated to renal 
potassium excretion, has also been identified in HIV infected 
individuals37. 
 
CHRONIC KIDNEY DISEASE 
 
a) HIV Associated  Nephropathy(HIVAN) 
 HIVAN represents a major complication of HIV infection. The 
evolution of HIVAN is the development of nephrotic syndrome initially 
and progress to ESRD in most patients38. 
 HIVAN has become the most common single diagnosis in HIV 
infected patients with renal insufficiency. The true prevalence of HIVAN is 
not exactly known but in a study conducted in South Africa incidence of 
HIVAN was found to be 77-85% in patients with persistent 
microalbuminuria. The geographic distribution of HIVAN is variable and 
depends on specific risk factors such as race, gender and drug use.  
 HIVAN is recognized throughout the spectrum of HIV disease. It 
can be the first manifestation of HIV infection or even precede detection  
of HIV antibodies39. Symptomatic HIVAN is now classified as clinical 
stage 4 disease by the WHO40. There is a marked racial predilection for the 
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development of HIVAN, as over 90% of patients are black, with a male 
predominance41. 30-60% of people with HIVAN are intra venous drug 
abusers42. The remainders are either homosexual or originate from regions 
where HIV infection is endemic. In approximately 10% of patients no 
specific risk factors of HIV can be identified.             
 Unfortunately, most patients who develop HIVAN do not have 
early signs or symptoms that would provide a clue to this diagnosis prior to 
the onset of progressive nephropathy. It is characteristically a disease in 
those of African descent and is less common in Europe and Asian 
populations43,44,45,46. 
Pathogenesis:-  
 The pathogenesis of HIVAN has been studied intensely over the 
past 15 years. The question in the pathogenesis of HIVAN is whether the 
disease can be attributed to direct viral effect or to HIV related changes on 
the cytokine milieu. HIVAN is caused by HIV gene expression in renal 
tissue, resulting in injury of glomerular and tubular epithelial cells. 
 Early studies using in situ hybridisation to a C-DNA probe found 
the HIV genome in tubular and glomerular epithelial cells in patients with 
HIVAN. Patient with immune mediated glomerulonephritis or HIV 
infected patients with no renal disease had less cellular involvement. 
 Since HIV proliferation appears to be major determinant of 
cytotoxicity, factors that precipitate viral replication within the kidney 
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could explain the sudden onset of the disease. Circularized viral DNA, a 
marker of recent nuclear import of full-length, reverse-transcribed RNA, 
was detected in the biopsies, suggesting active replication of HIV in renal 
tissue47. HIV proliferation is regulated by two genes nef and vif with 
opposing action. Minor mutations in either of these lead to rapid viral 
replication and death of the host cells. Others genes implicated are vpr,   
tat and rev. Concomitant infection with Viral hepatitis, Syphilis or CMV, 
could induce HIV replication. CMV may promote viral proliferation 
through a mechanism that is dependent on tumour necrosis factor (TNF)48. 
 HIV is a potent stimulator of TGF β, a cytokine strongly implicated 
in development of fibrosis. The transgenic mice model (Tg 26) suggests 
that activation of cytokine could be the basis for the extensive interstitial 
fibrosis and glomerular scleorsis that are hallmark of HIVAN49. 
 HIV RNA and protein markers specific for HIV have been 
demonstrated in tubular epithelium, glomerular epithelial cells and 
mesangial cells by a variety of techniques in vitro and in renal biopsy 
tissue of HIV patients50. 
 In transgenic mice model (Tg 26), HIV-1 envelope (gp 41 and gp 
120) and regulatory genes are expressed but gag and pol genes are deleted 
to render the virus non infectious. These mice develop a syndrome closely 
resembling HIVAN51. Kidneys were transplanted between normal and 
transgenic mice. HIVAN then developed in non transgenic mice, where as 
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the normal kidneys remained disease free in transgenic mice. This study 
provides evidence that HIVAN is caused by a direct HIV gene expression 
rather than the systemic effects of HIV infection52. 
 HIV infection may involve epithelial cells from multiple    
segments of the nephron including glomerulus (podocytes), tubule, thick 
ascending loop of  Henle and collecting duct. This pattern of involvement 
may explain the tubular dilatation seen in kidney biopsy of patients with 
HIVAN53. HIV-infection induces loss of contact inhibition54 and loss of 
podocyte differentiation markers and increases podocyte proliferation55,56. 
In addition, HIVAN showed a marked reduction in the expression of 
cyclins and cyclin-dependent kinase inhibitors which may account for the 
activation of podocyte proliferation in collapsing nephropathy57,58. 
 The kidney also seems to be the reservoir for HIV. Despite 
undetectable viral levels in serum, a case report described in a patient who 
continued to express HIV in renal epithelial cells determined by RNA in 
situ hybridization59. There is also compelling evidence that active 
replication of HIV occurs in kidney epithelium, possibly producing HIV 
strains in the kidney microenvironment that differ from HIV circulating in 
the blood. This suggests that kidney may serve as a viral reservoir 
harbouring HIV strains that have evolved under tissue specific selection 
process60. 
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Histopathology61:- 
 HIVAN is associated with characteristic glomerular, tubular, 
interstitial and ultra structural lesions. Autopsy data demonstrates that 90% 
of patients with the clinical diagnosis of HIVAN have focal and segmental 
glomerulosclerosis34. 
 Histopathologically classic HIVAN is a collapsing form of       
focal segmental glomerulosclerosis with podocyte hyperplasia and 
dedifferentiation associated with severe tubulopathy which is characterized 
by tubular apoptosis, microcytes and interstitial fibrosis. 
Light Microscopic Features:- 
¾ Collapsing Focal Segmental Glomerulosclerosis(FSGS) or 
mesangial hyperplasia. 
¾ Cystic tubular dilatation. 
¾ Interstitial oedema. 
¾ Cellular infiltration by T- lymphocytes or monocytes. 
¾ Dilated degenerating proximal tubules filled with eosinophilic 
material possibly representing cast formation in situ. 
Electron Microscopy Features:- 
¾ The presence of numerous tubuloreticular inclusions within the 
endothelial cells is an important finding in HIVAN. Finding 
numerous tubulointerstitial inclusions in capillary endothelial cells 
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in a patient with FSGS prompts some pathologists to request for 
HIV antibody testing. 
 Although renal tissue may stain for IgM, C1q, C3 and kappa (κ) or 
lambda (λ) light chains in areas of focal sclerosis, immunologic 
mechanisms are probably not central to genesis of HIVAN62. 
Clinical Presentation 
¾ Proteinuria but no hematuria. 
¾ Progressive renal failure 
¾ Absence of oedema or hypertension (due to volume depletion) 
¾ Proteinuria usually in nephrotic range (ranging from 1.7 – 40 
gm/day) - hallmark of HIVAN63. 
Investigation 
¾ Urine analysis: Often reveals severe proteinuria 2+ and more with 
oval fat bodies and frank lipiduria, presence of renal tubular 
epithelial cells in the urinary sediment. Broad waxy casts are also 
seen. 
¾ Microalbuminuria: Seen in 9-30% of untreated HIV patients in very 
early stages of disease course. 
¾ Azotemia. 
¾ Renal Ultrasound: Normal or enlarged kidneys with increased 
echogenicity. 
¾ Renal Biopsy: Reveals characteristic findings. 
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Management:- 
 Patients with HIVAN may experience rapid progression to ESRD.  
HAART delays progression to ESRD64, although a proportion of patients 
will still require renal replacement therapy despite HAART65. The 
incidence of HIVAN has decreased considerably in the HAART era, with 
risk reductions of approximately 60% in a multivariate analysis66. 
Available treatments options are 
¾ Anti Retroviral Therapy 
¾ Corticosteroids  
¾ ACE inhibitors or ARBs 
 
Anti Retroviral Therapy:-               
 Because HIV infection itself appears to be the cause of HIVAN, 
antiretroviral therapy is a logical choice as a therapy for HIV-related renal 
diseases. There appears to be a more beneficial effect of triple combination 
over Zidovudine monotherapy67.  PI-containing HAART had a lower rate 
of decrease in creatinine clearance compared with earlier monotherapy or 
dual therapy67. Direct beneficial effects of PIs on HIV-related kidney 
disease may include inhibition of apoptosis and superoxide generation, 
interference with the production and release of inflammatory cytokines and 
chemokines, and down-regulation of endothelial cell expression of 
adhesion molecules crucial in mediating leukocyte recruitment to sites of 
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inflammation68,69,70. In addition to being effective in treating established 
HIVAN, ART may decrease the actual incidence of de novo HIVAN66,71. 
Corticosteroids:-  
 In patients with progression despite HAART, corticosteroids are 
recommended on the basis of retrospective and prospective studies 
showing benefit29. In a large retrospective cohort analysis, corticosteroid 
therapy was associated with an improvement in creatinine clearance over 
time (+3.32 mL/min/month), compared with a deterioration (−5.57 
mL/min/month) in non–corticosteroid treated subjects67. One prospective, 
open-label study in patients receiving monotherapy or dual antiretroviral 
therapy showed a decrease in serum creatinine levels(mean decrease, 8.1-
3.0 mg/dL) and 24-hour urinary protein excretion (mean decrease, 9.1-3.2 
gm/day) with glucocorticoid therapy and infectious complications were 
infrequent72. 
ACE inhibitors:- 
 Angiotensin II increases the cellular synthesis of TGF β which has 
been implicated in the pathogenesis of HIVAN. ACE inhibitors are 
effective in slowing the progression of renal insufficiency by reducing 
production of TGF β in both humans and HIV transgenic mice73. 
Multivariate analysis revealed a reduced risk of renal failure, greater 
overall survival, improved creatinine levels, and stabilization of proteinuria 
associated with ACE inhibitors with no difference in exposure to 
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antiretroviral therapy74. Current guidelines reserve ACE inhibitor use to the 
subset of individuals with hypertension and proteinuria, with the goal of 
keeping blood pressure less than 125/75 mm Hg, in line with the K/DOQI 
recommendations for HIV-negative CKD29. 
 Renal biopsy should be offered to patients as treatment and 
prognosis vary according to the biopsy results. 
Risk factors for progression of renal disease include 
¾ Lower CD4 count. 
¾ Detectable HIV RNA levels. 
¾ Hypertension. 
¾ Hypoalbuminemia. 
¾ Elevated serum creatinine. 
 
b) Non HIVAN causes of CKD.  
 Non-HIVAN causes of CKD are more likely to occur in individuals 
who are not black, are normotensive, are hepatitis B coinfected, and have 
higher CD4 cell counts65.  
i. Immune Complex Disease 
            HIV associated immune mediated renal disease is the most 
common glomerular disease found on renal biopsy in series reported 
from Italy and France75,76. 
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 Important forms of HIV immune complex disease are 
¾ IgA nephropathy 
¾ Membrano Proliferative glomerulopathy 
¾ Lupus like nephropathy 
¾ Membranous nephropathy 
¾ Minimal change disease 
 
  HIV has been implicated as a stimulus for immune complex 
formation. Immune complexes with antigen have been identified in 
the circulation and the renal tissue. Complexes contain HIV antigen 
and antibody to gp 120, immunoglobulins, C1q and C3. Interstitial 
infiltrates are frequent with a higher frequency of B cells than in 
HIVAN and the progression to renal failure is slower than in 
HIVAN77. Renal biopsy is important in determining the histological 
diagnosis in patients with HIV infection and renal disease, including 
those who present with nephrotic range proteinuria and is the only 
definitive way to diagnose HIVICD65,79. In a recent U.S. multicenter 
observational study, patients with renal diseases other than HIVAN 
had a longer course until the development of ESRD and had better 
overall survival65. No differential effect of treatment with 
antiretroviral drugs was noted in the group of patients without 
HIVAN. 
39 
 
ii. Thrombotic Microangiopathies 
   May present as Haemolytic Uremic Syndrome (HUS) or 
Thrombotic Thrombocytopenic Purpura (TTP).  
           The diseases manifest their common presentations, but 
because of the protean manifestations of HIV infection, may prove 
difficult to diagnose. Abnormalities of the peripheral blood smear 
remain the criterion for making the diagnosis79. Although a variety 
of different therapeutic approaches have been employed, 
plasmapharesis remains the safest and perhaps the most effective 
treatment for HIV-infected patients with TTP80. The potential 
therapeutic role of antiretroviral therapy in such cases, while 
attractive on theoretical grounds has not been tested adequately in 
well-designed clinical studies. 
 
END STAGE RENAL DISEASE 
 HIVAN has become the third leading cause of ESRD among 
African Americans aged 20-64 yrs17,34. Black patients infected with HIV 
are at risk for the development of ESRD, irrespective of mode of viral 
acquisition. 
Management options include 
¾ Renal replacement in the form of Haemodialysis or Peritoneal 
Dialysis. 
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¾ Transplantation - Transplant in HIV-positive individuals is 
associated with higher serum creatinine levels and a greater 
incidence of rejection. On the basis of existing literature, it is 
reasonable for HIV-positive patients with ESRD to be offered living 
donor or deceased donor renal transplant if they have had an 
undetectable HIV viral load and a stable CD4 cell count of more 
than 200/µL for 6 months and are free of active opportunistic 
infections81. 
 
MICROALBUMINURIA IN HIV AND AIDS PATIENTS 
 Microalbuminuria is an independent and earliest marker of renal 
involvement and loss of endothelial integrity. Overall microalbuminuria is 
seen in ~ 20% (varying from 8.7% to 30% in various studies) of untreated 
HIV infected patients5,6,7,8,9,10 and significant proteinuria in 6%82. 
Microalbuminuria levels showed correlation with CD4 T cell count 
suggesting an association between progression of disease and 
microalbuminuria. Various studies were conducted to find out the 
incidence of microalbuminuria in HIV infected patients8,9.           
  Luke et al noticed abnormal urinary levels of microalbuminuria in 
19.4% of HIV positive patients9. Microalbuminuria did not correlate with 
race, sex, risk factor of AIDS, disease history or concurrent drug therapy. 
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 In contrast, urinary microalbumin levels correlated well with 
CD4 T cell and viral load suggesting an association between AIDS 
progression and microalbuminuria. 
 Busch et al8 study found that albuminuria occurred frequently with 
CD4 counts below 200/µL and also concluded that subclinical renal 
involvement is not uncommon in HIV infection with T4 cell counts > 200/ 
µL. 
 Present study was undertaken to investigate microalbuminuria in 
HIV patients in South India where investigators have shown that at CD4 
counts between 200-350/µL South Indians have higher viral load than     
that suggested by International AIDS Society. 
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MATERIALS AND METHODS 
 
Setting: This study was carried out at Government Kilpauk Medical   
                College & Hospital, Chennai . 
Collaborating department: ART Centre & 
                                             Department of Internal Medicine. 
 
Study design                                   : Cross Sectional Study 
 
Period of study                               : January 2008 - September 2008 
 
Sample size                                     :  80 cases 
 
Ethical Committee Approval         :  Obtained  
 
Informed Consent                          :  Obtained 
 
Conflict of Interest                         :  There was no conflict of interest  
 
Financial Support                          :   Nil 
 
 
 
 
 
 
 
 
43 
 
Selection and details of study subjects: 
 The study was conducted in HIV positive patients who were 
attending the ART clinic, Government Kilpauk Medical College & 
Hospital, Chennai. 
 
Inclusion criteria: 
 Adult male & non pregnant female HIV infected patients before 
ART therapy. 
 
Exclusion criteria: 
¾ Children 
¾ Overt renal disease 
¾ Diabetes mellitus 
¾ Systemic hypertension 
¾ Collagen vascular disease 
¾ Urinary tract infection 
¾ Hepatitis 
¾ Patients on nephrotoxic agents 
¾ Patient not willing for study 
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 The total number of HIV positive patients screened were 270,  of 
which 90 patients had Tuberculosis infection (pulmonary & extra 
pulmonary) and they were on Anti Tuberculosis Treatment, so they were 
excluded from study. 35 patients who had Diabetes Mellitus were excluded 
from the study. 
  27 cases were associated with Systemic Hypertension and hence 
where excluded from the study.  The patients with NSAID abuse were 
found to be 16 in numbers and they were excluded from study. 10 patients 
were found to be having Overt Renal Disease and they were excluded from 
the study. 12 patients had Urinary Tract Infection evidenced by urinary 
examination and they were excluded from the study. 
 After exclusion of these patients, the number of patients selected 
for our study was 80. They were divided into 2 groups according toCD4 
count. 40 patients with CD4 count of ≤ 350 cells/ µL were grouped as 
Group A. Similarly 40 patients with CD4 count of > 350 cells/µL were 
grouped as Group B. 
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LIMITATION 
 
1. Due to technical and financial constraints only 80 cases could 
measured for microalbuminuria. 
2. Only microalbuminuria & 24 hours urinary protein was 
measured. 
3. Renal biopsy was not attempted due to ethical reason. 
4. Long term follow up was not attempted. 
5. Effect of ART on microalbuminuria was beyond the purview 
of the study. 
6. Viral load could not be estimated due to constraints. 
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METHODOLOGY 
 Selected socio-demographic, clinical data were elicited and few 
necessary investigations were done and data was recorded in a profoma. 
I. Socio – demographic data: 
 Age 
 Sex 
 Occupation 
II. Clinical data: 
 Clinical examination 
 WHO clinical staging 
III. Laboratory data: 
HB%        TC           DC:   P    L    E   M    B     ESR 
URINE:  ALBUMIN          SUGAR         DEPOSITS   
BLOOD: SUGAR             UREA 
SERUM: CREATININE      ELECTROLYTES - Na+      K+ 
SERUM: BILIRUBIN               SGOT          SGPT           
               ALKALINE PHOSPHATASE 
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URINE: MICROALBUMIN & ALBUMIN CREATININE RATIO   
            24 hr urine was collected. Patients were advised to avoid strenuous 
exercise, high protein diet during the period of collection of urine sample 
Albumin level in urine was measured by Immunoturbidometry technique83. 
Creatinine levels were measured using Jaffe method. 
             24 HOURS URINE PROTEIN. . 
CD4 COUNT:  
  CD4 count was done using flow cytometry84. A computer calculates 
the number of CD4 T cells by analyzing the size of the cell and which of 
the antibodies it has been tagged with. The overall process is called 
Fluorescence Activated Cell Sorting (FACS)85. 
CHEST X-RAY  
ECG 
USG – ABDOMEN & KUB 
 
IV. Statistical analysis 
 Data was entered in Microsoft excel spread sheet and analyzed 
statistically using SPSS software version 11.5. 
Following tests were used to check for statistical significance. 
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1. Two sample independent‘t’ test. 
2. Mann-Whitney U rank non – parametric test. 
3. Chi-Square test. 
4. Binary Logistic Regression Model. 
 Results were considered significant if the ‘p’ value was below 0.05. 
REFERENCE VALUE USED IN THIS STUDY 
BMI 80 
Body Mass Index = Weight (kg) / Height (m2). 
Values        18.5 - 22.9 kg / m2 was taken as normal weight 
  < 18.5 kg / m2 was taken as underweight 
  23- 24.9 kg / m2 was taken as overweight 
  ≥ 25 kg / m2 was taken as obesity  
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CASES SCREENED – FLOW CHART 
 
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Cases with HIV positivity screened 
                                  (n=270) 
  Cases included for study 
                  (n=80)          
 Cases excluded from study 
                     (n=190) 
Pts. with PT/EPT on ATT   (n=90) 
Diabetes Mellitus                (n=35) 
NSAID abuse                      (n=16) 
Hypertension                       (n=27) 
Overt Renal disease    (n=10) 
Urinary Tract Infection       (n=12) 
 
  Group B 
(CD4 count 
> 350/mm3) 
    (n=40) 
 
  Group A 
(CD4 count 
< 350/mm3) 
    (n=40) 
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RESULTS 
 A total of 80 HIV seropositive patients were studied. They were 
divided into two groups. 
 Group A included 40 HIV seropositive patients with CD4 cell count          
≤ 350/ µL (n=40) 
 Group B included 40 HIV seropositive patients with CD4 cell count          
> 350/ µL (n=40) 
 Mean CD4 count of study group was 387.7 ± 193.78 cells/µL (Group 
A – 236.75 ± 79.77 cells/µL. Group B – 538.65 ± 151.53 cells/µL.) 
 Out of 80 patients 41 (51.25%) were males ( Group A – 21, Group – 
B 20) and 39 (48.75%) were females (Group A -19, Group B – 20) 
 Mean age group of study population was 33.85 ± 8.26 years (Group A 
– 35.65 ± 9.80 years. Group B – 32.05 ± 6.46years) 
 House wives and others constituted the majority of study group 
occupation about 35% and 40% respectively. 
 Heterosexual route was the most common mode of transmission of 
HIV infection about 91.25%. 
 Mean BMI of study group was 21.66 ± 3.33 kg/m2 (Group A – 19.92 
± 2.65 kg/m2. Group B 22.4 ± 4.02 kg/m2) 
 None of the patients in study group had symptoms pertaining to renal 
pathology. 
51 
 
 Nine patients (11.25%) (Group A - 9; Group B - 0) had 
Microalbuminuria. 
 Six patients (7.5%) (Group A - 6; Group B - 0) had Overt proteinuria. 
 Eight patients (10%) (Group A - 7; Group B - 1) had elevated levels 
of Serum Creatinine. 
 Significant correlation was found between microalbuminuria and  
CD4 count,   
 No significant correlation was found between microalbuminuria and 
Age, Sex, Body Mass Index & WHO staging. 
 
 
CD4 GROUP  
                                           Table - 5 
CD4 
Group 
Number 
of patients
CD4 count  
cells/µL 
MeanCD4 
count cells/µL 
A 40 ≤ 350 236.75 ± 79.77 
B 40 > 350 538.65 ± 151.53 
Total 80  387.70 ± 193.78 
                                           
 Mean CD4 count of Group A was 236.75 ± 79.77 cells/µL. 
Mean CD4 count of Group B was 538.65 ± 151.53 cells/µL. 
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AGE DISTRIBUTION AND CD4 COUNT 
Table – 6 A 
CD4 Group Age 
Group A B Total 
21 – 30 17         (42.5%) 
21      
(52.5%) 
38        
(47.5%) 
31 – 40 12         (30%) 
16          
(40%) 
28           
(35%) 
41 – 50 9         (22.5%) 
2           
(5%) 
11      
(13.75%) 
> 50 2           (5%) 
1          
(2.5%) 
3          
(3.75%) 
Total 40         (100%) 
40          
(100%) 
80         
(100%) 
 
 
Table – 6 B 
AGE CD4 Group Mean SD 
A 35.7 9.8 
B 32.1 6.5 
 
p value = 0.163   Not significant. 
Mean age of Group A was 35.65 ± 9.80 years. 
Mean age of Group B was 32.05 ± 6.46 years. 
There was no statistically significant difference in distribution with respect 
to Age between two groups. 
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SEX DISTRIBUTION AND CD4 COUNT  
                                                         Table-7 
CD4 GROUP SEX 
A B 
TOTAL 
MALE 21     (52.5%) 
20     
(50%) 
41     
(51.25%) 
FEMALE 19    (47.5%) 
20     
(50%) 
39     
(48.75%) 
 
       p value = 0.823.  Statistically not significant. 
There was no statistically significant difference in the distribution with 
respect to Sex between two groups. 
AGE DISTRIBUTION IN RELATION TO SEX AND CD4 COUNT 
Table – 8 
Group A Group B Age 
Group Male Female Male Female 
21 – 30 7 10 10 11 
31 – 40 7 5 7 9 
41 – 50 5 4 2 0 
> 50 2 0 1 0 
Total 21 19 20 20 
 
p value for Group A = 0.41  Not significant. 
p value for Group B = 0.35  Not significant. 
This table shows that there is no statistically significant difference in 
distribution with respect to Age & Sex within each Group.    
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OCCUPATION DISTRIBUTION AND CD4 COUNT 
Table-9 
   Occupation Total 
House wife 28             (35%) 
Coolie 17              (21.25%) 
Watchman 2               (2.5%) 
Driver 1              (1.25%) 
Others 32              (40%) 
Total 80             (100%) 
 
                     
WHO STAGING - DISTRIBUTION AND CD4 COUNT 
Table – 10 
CD4 count WHO 
Staging A B Total 
1 16        (40%) 
35     
(87.5%) 
51 
(63.75%) 
2 9       (22.5%) 
2          
(5%) 
11 
(13.75%) 
3 13     (32.5%) 
3         
(7.5%) 
16           
(20%) 
4 2          (5%) 0 
2            
(2.5%) 
Total 40      (100%) 
40      
(100%) 
80 
(100%) 
 
p value = 0.000  Significant. 
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There was statistically significant difference in the distribution with respect 
to WHO staging between two groups. 
ROUTE OF TRANSMISSION – DISTRIBUTION  
Table – 11 
Route of Transmission Total 
Heterosexual 73            (91.25%) 
Blood Transfusion 3               (3.75%) 
Intravenous Drug User 2                (2.5%) 
Others 2               (2.5%) 
 
 
BMI GROUP – DISTRIBUTION AND CD4 COUNT 
Table-12A 
CD4 Group BMI Group     
(kg / m2 ) A B Total 
< 18.5 5   (12.5%) 
4      
(10%) 
9   
(11.25%) 
18.5 - 22.9 29 (72.5%) 
18    
(45%) 47  (58.75% 
23 - 24.9 4      (10%) 
11 
(27.5%) 
21 
(26.25%) 
≥ 25 2        (5%) 
7     
(17.5%) 
3     
(3.75%) 
Total 40  (100%) 
40  
(100%) 
80    
(100%) 
 
p value = 0.033  Significant. 
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There was statistically significant difference in distribution with 
respect to Body Mass Index between two groups. 
  Table – 12B 
Body Mass Index       
(kg/m2) CD4 Group 
Mean SD 
A 19.91 2.65 
B 22.4 4.02 
 
p value = 0.002   Significant. 
Mean BMI of Group A patients was 19.91 ± 2.65 kg/m2. 
Mean BMI of Group B patients was 22.40 ± 4.02 kg/ m2. 
Body Mass Index was lower in patients with CD4 Group A compared to 
Group B indicating a possible direct proportional relation between CD4 
count & BMI. 
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MICROALBUMINURIA 
DISTRIBUTION IN RELATION TO CD4 COUNT 
Table – 13A 
CD4 Group Microalbuminuria A B Total 
Absent 31  (77.5%) 
40 
(100%) 
71  
(88.75%) 
Present 9   (22.5%) 0 
9   
(11.25%) 
Total 40  (100%) 
40  
(100%) 
80   
(100%) 
 
p value = 0.001  Significant 
This table shows statistically significant difference in distribution of 
prevalence of microalbuminuria with CD4 count. 9 out of 40 patients in 
Group A with CD4 count ≤ 350 had microalbuminuria. None of the 
patients in Group B with CD4 count > 350 had microalbuminuria. 
Table – 13 B 
Urine Microalbumin  
(mg/day) CD4 Group
Mean SD 
A 37.95 33.75 
B 12.13 5.96 
 
p value = 0.000  Significant. 
Mean value of urine microalbumin in Group A is 37.95 ± 33.75 mg/day. 
Mean value of urine microalbumin in Group B is 12.13 ± 5.96 mg/day.    
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DISTRIBUTION IN RELATION TO AGE & SEX 
Table – 14 
Group A Age Group Male Female 
21 – 30 1 2 
31 – 40 3 1 
41 – 50 0 1 
> 50 1 1 
Total 5 4 
 
p value = 0.35  Not significant 
There is no statistically significant difference in distribution of prevalence 
of microalbuminuria with respect to Age & Sex in Group A patients.  
URINE ALBUMIN CREATININE RATIO DISTRIBUTION IN 
RELATION TO CD4 GROUP 
Table – 15 
Urine Albumin       
Creatinine Ratio (mg/gm) CD4 Group Mean SD 
A 36.78 31.86 
B 13.4 5.86 
 
p value = 0.000  Significant. 
Mean urine albumin creatinine ratio of Group A was 36.78 ± 31.86 mg/gm. 
Mean urine albumin creatinine ratio of Group B was 13.40 ± 5.86 mg/gm. 
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OVERT PROTEINURIA DISTRIBUTION IN RELATION TO CD4 
GROUP 
Table – 16 A 
CD4 Group Overt 
Preoteinuria A B Total 
Absent 34     (85%) 
40   
(100%) 
74     
(92.5%) 
Present 6       (15%) 0 
6       
(7.5%) 
Total 40   (100%) 
40   
(100%) 
80    
(100%) 
 
p value = 0.011  Significant. 
This table shows statistically significant difference in distribution of 
prevalence of overt proteinuria with CD4 count. 6 out of 40 patients in 
Group A with CD4 count ≤ 350 had overt proteinuria. None of the patients 
in Group B with CD4 count > 350 had overt proteinuria. 
Table – 16 B 
24 Hours Urine Protein 
(mg/day) CD4 Group 
Mean SD 
A 227.98 104.37 
B 144.18 43.42 
 
 p value = 0.000  Significant. 
Mean 24 hours urine protein level in Group A is 227.98 ± 104.37 mg/day. 
Mean 24 hours urine protein level in Group B is 144.18 ± 43.42 mg/day. 
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SERUM CREATININE DISTRIBUTION IN RELATION TO CD4 
GROUP 
Table – 17 A 
CD4  Group Serum 
Creatinine A B Total 
Elevated 7        (17.5%) 
1         
(2.5%) 
8     
(10%) 
Normal 33     (82.5%) 
39     
(97.5%) 
72   
(90%) 
Total 40      (100%) 
40      
(100%) 80    (100) 
 
 p value = 0.025  Significant. 
There is statistically significant difference in distribution of prevalence     
of elevated serum creatinine levels between two groups. 
Table – 17 B 
Serum Creatinine     
(mg/dl) CD4 Group 
Mean SD 
A 0.89 0.19 
B 0.83 0.09 
 
 p value = 0.056  Not significant.                                                                 
Though there is statistically significant difference in distribution of 
prevalence of elevated creatinine levels, difference is not significant in 
actual distribution. 
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BLOOD UREA DISTRIBUTION IN RELATION TO CD4       
GROUP 
Table – 18 
Blood Urea              
(mg/dl) CD4 Group 
Mean SD 
A 24.45 7.84 
B 21.2 3.77 
 
p value = 0.021  Significant. 
There was statistically significant difference in distribution with respect to 
blood urea between two groups. 
Mean blood urea level in Group A was 24.45 ± 7.84 mg/dL. 
Mean blood urea level in Group B was 21.20 ± 3.77 mg/dL. 
BLOOD SUGAR DISTRIBUTION IN RELATION TO CD4    
GROUP 
Table – 19 
Blood Sugar            
(mg/dl) CD4 Group 
Mean SD 
A 89.55 21.48 
B 87.73 18.25 
 
 p value = 0.683  Not significant. 
There was no statistically significant difference in distribution with respect 
to blood sugar between two groups. 
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SERUM SODIUM DISTRIBUTION IN RELATION TO CD4 
GROUP 
Table – 20 
Serum Sodium       
(meq/L) CD4 Group 
Mean SD 
A 139.63 2.65 
B 139.18 2.24 
 
p value = 0.414  Not significant. 
There was no statistically significant difference in distribution with respect 
to serum sodium between two groups. 
SERUM POTASSIUM DISTRIBUTION IN RELATION TO CD4 
GROUP 
Table - 21 
Serum Potassium   
(meq/L) CD4 Group 
Mean SD 
A 3.84 0.53 
B 3.9 0.17 
 
p value = 0.476  Not significant. 
There was no statistically significant difference in distribution with respect 
to serum potassium between two groups. 
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BINARY LOGISTIC REGRESSION MODEL 
This test was applied to all the patients to assess the correlation of 
various risk factors with microalbuminuria. 
Dependent variable:  Microalbuminuria. 
Risk factors assessed: Age, Sex, Body Mass Index, WHO staging and CD4 
count. 
Risk factor significant: CD4 count. 
Table - 22 
Name of the 
variable p value 
Odds 
ratio 
Age 0.733 0.795 
Sex 0.782 1.016 
WHO Staging 0.789 1.132 
Body Mass Index 0.208 1.192 
CD4 count 0.011 0.99 
 
From the above table it is evident that CD4 count alone correlates 
with prevalence of microalbuminuria in our study group. Prevalence of 
microalbuminuria increases as CD4 count comes down. In our study 
microalbuminuria is seen in patients with CD4 count ≤ 350 cells/µL with a 
prevalence rate of 11.25%. 
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                         DISCUSSION 
 HIV infection is the pandemic of modern era. Renal            
disorders are encountered in all stages of HIV infection. 
 Microalbuminuria is the earliest marker of the renal involvement, 
seen in approximately 20% (8.7-30% in various studies) of untreated HIV 
infected patients5,6,7,8,9,10.. 
 HIVAN has become the third leading cause of ESRD among 
African Americans aged 20-64 years17,34. 
 Ramalingam et al21 in a study conducted in 2001 have shown that  
mean CD4 counts in South Indian population, both normal and HIV 
infected individuals  are lower than in western population and have 
proposed a modified classification based on CD4 cell count for South 
Indians. The categories of CD4 count proposed were cell count > 300,    
81-300, ≤ 80 cells/µL, instead of the > 500, 201-500, ≤ 200 recommended 
by CDC. 
           Kannagai et al22 in a study conducted  in 2008 have shown that   
majority of  HIV infected individuals in South India with CD4 counts       
of 200-350 cells/µL had higher viral load than that suggested by                   
International AIDS Society. 
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 Present study was undertaken based on above observations.         
There are no supportive studies showing the comparison of prevalence               
of microalbuminuria in CD4 counts ≤ 350/µL & > 350/µL. 
MICROALBUMINURIA 
 Luke DR et al9 observed that microalbumin levels did not correlate 
with age or sex. In our study also there was no correlation of microalbumin 
levels with age or sex. 
 The prevalence of microalbuminuria in HIV and AIDS patients 
differ in various studies. Morten Baekken et al6 study showed 
microalbuminuria in 8.7% of HIV infected patients. Lynda Anne Szczech 
et al7 study showed that microalbuminuria was present in 11% of HIV 
infected patients. Busch HW et al8 study showed microalbuminuria in 13% 
of HIV patients. Luke DR et al9 study noted 19.4% of HIV patients had 
microalbuminuria. Kimmel PL et al10 study showed microalbuminuria in 
20 to 30% of HIV patients. 
 In our study the prevalence of microalbuminuria was found to be 
11.25%.  All the 9 patients who had microalbuminuria belonged to Group 
A.  The mean urine microalbumin level was 37.95 mg/day (SD 33.75).  
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URINE ALBUMIN CREATININE RATIO  
 Kimmel PL et al, Umana WO et al87 noticed that, the prevalence of    
an increased urine albumin creatinine ratio amounting to microalbuminuria 
was 29.8% in the HIV infected patients. In   Busch HW et al8 study, the 
prevalence rate was 13.4%. In Lynda Anne Szczech et al7 study, the 
prevalence rate was 11%. 
  In our study the prevalence of elevated urine albumin creatinine 
ratio amounting to microalbuminuria was seen in 11.25% of study group. 
All the 9 patients who had elevated urine albumin creatinine ratio belonged 
to Group A.  The mean urine albumin creatinine ratio is 36.78 mg/gm (SD 
31.86). 
OVERT PROTEINURIA 
 Several studies have suggested that abnormality of protein 
excretion without frank nephritic syndrome is common in HIV infected 
populations. In Agaba EL et al88 study proteinuria was detected in 25.3% 
Of HIV patients. In Cravley ST et al89 study the prevalence of 
asymptomatic proteinuria was 14% and the presence of proteinuria did not 
correlate with viral load. Varma PP et al90 study showed overt proteinuria 
in 17.6% of HIV patients. In Gardener et al91 study overt proteinuria was 
present in 11.2% of HIV seropositive women. Lynda Anne Szczech92 et al 
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study showed overt proteinuria in 14.1% of HIV seropositive women. 
Amitis Ramezaniab et al93 study showed overt proteinuria in 12.3% of HIV 
infected persons.  
 In our study, 7.5% of the study group had overt proteinuria. All the 
6 patients with overt proteinuria belonged to Group A. Mean urine 24 
hours urine protein was 227.98 mg/day (SD 104.37). 
CORRELATION OF MICROALBUMINURIA 
 Various studies show that there is a strong correlation between CD4 
count and microalbuminuria level. Szczech LA et al94, Busch HW et al8 
and Atta MG et al95 studies confirmed that microalbuminuria is commonly 
seen with CD4 counts ≤ 200/µL. Busch HW et al8 in their study also 
concluded that subclinical renal involvement is not uncommon in HIV 
infection with T4 cell counts > 200/µL.  
 In our study 9 out of 80 patients had microalbuminuria and all the 
patients with microalbuminuria were found to have CD4 count ≤ 350/µL 
and no patients with CD4 count > 350/µL had microalbuminuria. 
 Binary logistic regression model was applied to all patients to 
assess correlation of various risk factors with prevalence of 
microalbuminuria. Statistically significant correlation was seen between 
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prevalence of microalbuminuria and CD4 count. Microalbuminuria was not 
correlating with Age, Sex, WHO staging and Body Mass Index. 
UREA & CREATININE 
 In our study abnormal levels of serum creatinine not amounting to 
renal failure was found in 4 male and 4 female patients, of which 7 were 
found to have CD4 count ≤ 350/µL. There was statistically significant 
difference between distributions of blood urea with respect to CD4 group.  
 Though there was biochemical evidence of mild renal failure, they 
did not reveal any symptoms related to renal involvement. Thus this study 
showed that HIV infected and AIDS individuals may have asymptomatic 
renal involvement. 
 No electrolyte abnormalities were seen in our study. However the 
review of literature showed that the commonest fluid and electrolyte 
abnormality seen in HIV and AIDS cases is hyponatremia.  
 Behar DM et al96 and Winston JA97 et al studies show that type of 
renal involvement varied in different geographic regions. Studies in USA 
have shown high prevalence of Classical HIVAN. European studies from 
the United Kingdom and Italy emphasize a high proportion of patients with 
nephrotic syndrome in the setting of HIV infection have 
glomerulonephritis76,98 . A study from Thailand of HIV infected patients 
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with renal disease reported a diverse set of glomerulonephritis, but no cases 
of classic HIVAN46. 
 Christina M. Wyatt in her publication has mentioned about racial 
disparities in renal manifestations of HIV infection99. While in general, 
patients of African heritage are more likely to have HIVAN, European and 
Asian populations more often appear to have glomerulonephritis45,46,75,98.  
 Gardener, Lytt I et al91, showed proteinuria or elevated serum 
creatinine in HIV infected women were associated with an increased risk of 
death after controlling the other risk factors.  
 HIV infection is well known to involve kidneys and moderate to 
severe renal involvement has shown to worsen the HIV status, hence HIV 
infected patients have to be closely monitored for their renal involvement 
in its early phase and managed appropriately. 
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SUMMARY 
 The present study was aimed to study the prevalence of 
microalbuminuria in HIV seropositive patients and also to find out its 
correlation with CD4 counts. With rigid criteria 80 HIV seropositive cases 
were selected. There were 41 males and 39 females in the study group. 
 Prevalence of microalbuminuria in this study was 11.25%. The 
mean urine microalbumin level was 37.95 ± 33.75 mg/day. 
 This study showed prevalence of elevated urine albumin creatinine 
ratio amounting to microalbuminuria in 11.25%. The mean urine albumin 
creatinine ratio was 36.78 ± 31.86 mg/gm.  
 This study showed overt proteinuria in 7.5% of HIV seropositive 
patients. 
 Microalbuminuria levels specifically correlated with CD4 counts. 
In this study 9 out of 9 patients with microalbuminuria were found to have 
CD4 counts ≤ 350/µL. 
 Present study revealed abnormalities of serum creatinine in 8 
patients of which 7 patients were found to have CD4 counts ≤ 350/µL. 
 Present study recommends urinary screening for microalbuminuria 
in HIV patients to identify early renal involvement and minimize renal 
complications by early intervention. 
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CONCLUSION 
 Microalbuminuria was significantly elevated in the study group, seen 
in 11.25% of cases. The mean urine microalbumin value was 37.95 
mg/day. 
 The prevalence of elevated urine albumin creatinine ratio amounting 
to microalbuminuria was 11.25% in the study group. The mean urine 
albumin creatinine ratio was 36.78 mg/gm. 
 The microalbuminuria specifically correlated with CD4 counts, 9 out 
of 9 in the study group were found to have CD4 count ≤ 350/µL. 
 Serum Creatinine levels were elevated in 8 patients, out of whom 7 
were found to have CD4 count ≤ 350/µL. 
 Overt proteinuria was present in 7.5% in the study group. 
 Electrolyte abnormalities were not found in our study. 
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PROFORMA 
MICROALBUMINURIA  IN  HIV PATIENTS 
NAME:                                             AGE:         SEX: HOSPITAL 
NO: 
ADDRESS:           OCCUPATION:     
CD4 count                         WHO STAGING:                                   
PRESENT COMPLAINTS: 
  LOSS OF APETITE   
  VOMITING 
  BREATHLESSNESS 
  FREQUENCY OF MICTURITION 
  OLIGURIA 
  LEG SWELLING 
  FACIAL PUFFINESS 
  HEMATURIA 
  ABDOMINAL PAIN   
PAST ILLNESS 
  ATT INTAKE                                                DIABETES MELLITUS 
  HYPERTENSION                                          CORONARY ARTERY DISEASE 
  RENAL DISEASE                                          JAUNDICE 
  NSAID OR OTHER DRUG INTAKE 
  BLOOD TRANSFUSION                              OTHERS (SPECIFY) 
PERSONAL HISTORY 
  SMOKER                                                        ALCOHOLIC 
  MARITAL STATUS                                       SEXUAL PROMISCUITY 
  IV DRUG ABUSE 
GENERAL EXAMINATION: 
  HEIGHT :                        WEIGHT:  BMI:    
  PULSE:                                             BP: 
  ANAEMIA                       JAUNDICE                        CLUBBING                                           
  PEDAL EDEMA    LYMPHADENOPATHY 
SYSTEM EXAMINATION  
  CVS 
  RS 
  ABDOMEN 
  CNS 
 
INVESTIGATION 
 HB%             TC                 DC:   P      L       E     M     B              ESR 
 URINE:  ALBUMIN                  SUGAR                DEPOSITS    
     
BLOOD:  SUGAR                                 UREA 
SERUM:  CREATININE                      ELECTROLYTES – Na+              K+ 
SERUM  BILIRUBIN      SGOT       SGPT               SAP  
  
URINE:  MICROALBUMIN      
    24 HRS URINE PROTEIN  
                ALBUMIN CREATININE RATIO    
                  
CHEST  X-RAY                                                        ECG    
  
USG – ABD & KUB 
 4040
CD4 GROUPS
Group B Group A
 
 
  
 
 
CD4 GROUP DISTRIBUTION IN RELATION TO AGE & SEX 
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